A5031214793- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- Monoclonal and Polyclonal Antibodies Research
- Liver Diseases and Immunity
- Toxin Mechanisms and Immunotoxins
- Liver Disease and Transplantation
- Systemic Lupus Erythematosus Research
- Transgenic Plants and Applications
- Microbial Inactivation Methods
- interferon and immune responses
- Immunotherapy and Immune Responses
- Animal Virus Infections Studies
- Employment and Welfare Studies
- Respiratory viral infections research
- Diphtheria, Corynebacterium, and Tetanus
- Chronic Lymphocytic Leukemia Research
- Congenital Heart Disease Studies
- SARS-CoV-2 and COVID-19 Research
- Dermatology and Skin Diseases
- Bacterial Infections and Vaccines
- Advancements in Transdermal Drug Delivery
- Viral gastroenteritis research and epidemiology
- Medical Practices and Rehabilitation
- Workplace Health and Well-being
Karolinska University Hospital
2003-2021
Karolinska Institutet
2003-2021
AbbVie (United States)
2018
University of Gothenburg
2009-2013
Inovio Pharmaceuticals (United States)
2007-2011
Vertex Pharmaceuticals (United States)
2011
Institute of Medicinal Plant Development
2011
Background High baseline levels of IP-10 predict a slower first phase decline in HCV RNA and poor outcome following interferon/ribavirin therapy patients with chronic hepatitis C. Several recent studies report that single nucleotide polymorphisms (SNPs) adjacent to IL28B spontaneous resolution infection treatment among genotype 1 infected patients. Methods Findings In the present study, we correlated occurrence variants at three such SNPs (rs12979860, rs12980275, rs8099917) pretreatment...
Abstract The mechanisms by which in vivo electroporation (EP) improves the potency of i.m. DNA vaccination were characterized using hepatitis C virus nonstructural (NS) 3/4A gene. Following a standard injection with or without EP, plasmid levels peaked immediately at site and decreased 4 logs first week. In EP did not promote persistence and, depending on dose, was cleared almost after 60 days. imaging immunohistochemistry revealed that protein expression restricted to despite detection...
High systemic levels of interferon-gamma-inducible protein 10 kDa (IP-10) at onset combination therapy for chronic hepatitis C virus (HCV) infection predict poor outcome, but details regarding the impact IP-10 on reduction HCV RNA during remain unclear. In present study, we correlated pretreatment in liver biopsies (n = 73) and plasma 265) with throughout within a phase III treatment trial (DITTO-HCV). Low or intrahepatic were strongly associated pronounced first 24 hours all patients ( P...
<b>Background:</b> The hepatitis C virus (HCV) mutates within human leucocyte antigen (HLA) class I restricted immunodominant epitopes of the non-structural (NS) 3/4A protease to escape cytotoxic T lymphocyte (CTL) recognition and promote viral persistence. However, variability is not unlimited, sometimes almost absent, factors that restrict have been defined experimentally. <b>Aims:</b> We wished explore whether CTL epitope at residues 1073–1081 NS3 was limited by fitness. <b>Patients:</b>...
ABSTRACT Increasing levels of plasmid vector-mediated activation innate immune signaling pathways is an approach to improve DNA vaccine-induced adaptive immunity for infectious disease and cancer applications. Retinoic acid-inducible gene I (RIG-I) a critical cytoplasmic double-stranded RNA (dsRNA) pattern receptor required in response viral infection. Activation RIG-I leads type interferon (IFN) inflammatory cytokine production through promoter stimulator 1 (IPS-1)-mediated regulatory...
Several studies have shown that chronic hepatitis C (CHC) infection has a negative impact on kidney function, as well survival, in patients with disease (CKD) or hemodialysis. The aim of this nationwide registry study was to describe renal Swedish CHC.In the present study, were identified for CHC (B18.2) and CKD (N18) according International Classification Diseases (ICD)-10 inpatient care day surgery (1997-2013) non-primary outpatient (2001-2013) patient registries. Hemodialysis defined...
Previous studies on hepatitis C cascade of care have been mainly focused diagnosis and treatment rate, while less attention has given to patients lost follow-up (LTFU) after diagnosis. Analyses this latter issue population level are missing.In nationwide study people with HCV, we aimed estimate the proportion LTFU HCV diagnosis, characterize them, analyze their other healthcare contacts.Patients diagnosed chronic in Swedish National Patient Register during 2001-2011 still alive December 31,...
Single nucleotide polymorphisms (SNPs) upstream of IL28B predict the outcome treatment in chronic hepatitis C virus (HCV) infection, but their impact on viral kinetics and relation to other predictors are not well known. Here, two SNPs, rs12979860 rs8099917, were analysed related early during 110 patients with HCV genotype 1 infection. The reduction RNA after 7 days therapy was more pronounced (P < 0.0001) CC(rs12979860) or TT(rs8099917) than carrying TT(rs12979860) GG(rs8099917),...
The hepatitis C virus (HCV)-specific T cell response in patients with chronic HCV is dysfunctional. In this study, we aimed at restoring immunological function through therapeutic vaccination a transgenic mouse model impaired HCV-specific responses due to persistent presence of hepatic nonstructural (NS)3/4A Ags. cells have an actively maintained dysfunction reflected reduced frequency, cytokine production, and effector vivo, which can be partially restored by blocking regulatory or...
<h3>Background</h3> The non-structural (NS) 3/4A protease/helicase of the hepatitis C virus is known to modulate signalling pathways in infected hepatocyte by cleaving CARD adaptor inducing IFNβ (Cardif), T-cell protein tyrosine phosphatase (TC-PTP) and TIR domain-containing (TRIF), but effects NS3/4A vivo still remain unclear. <h3>Aim</h3> To investigate influence on intracellular intercellular analysing intrahepatic inflammatory response naïve, lipopolysaccharide (LPS)/d-galactosamine...
Purpose: The aim of this study was to estimate the prevalence physician-diagnosed and registered chronic hepatitis C (CHC), reported frequencies Charlson comorbidities compared with matched comparators from general population.Materials methods: Patients were identified according ICD codes for CHC in Swedish National Patient Register (1997–2013). Prevalence estimated different patient identification algorithms subgroups. ascertained same register age/sex/county residence population...
Background Interferon and ribavirin therapy for chronic hepatitis C virus (HCV) infection yields sustained virological response (SVR) rates of 50–80%. Several factors such as non-1 genotype, beneficial IL28B genetic variants, low baseline IP-10, the functionality HCV-specific T cells predict SVR. With pending introduction new therapies HCV entailing very rapid clearance plasma RNA, importance biomarkers likely will increase in order to tailor therapy. CD26 (DPPIV) truncates chemokine IP-10...
The hepatitis C virus nonstructural (NS) 3/4A protease sequence is highly conserved for reasons not fully understood. We determined the activity in 181 NS3/4A gene products which each residue was replaced by alanine or glycine. Unexpectedly, most (87%) residues could be and would retained. Using these data, we were able to identify a human leukocyte antigen A2-restricted epitope substitutions at 5 of 9 destroyed protease. NS3 shows an unexpectedly high plasticity, it therefore important...
Hepatitis C is highly prevalent among people who use drugs (PWUD), and the hepatitis virus (HCV) epidemic less characterised in Norway. The aims of study were to assess prevalence treatment willingness high-risk populations by reaching out frequently visited sites for populations.Individuals from included September 2015 March 2017. Two dedicated nurses local opioid substitution clinic, outpatient clinics, PWUD day centres, prison, refugee centre Trondheim, Demographic data, risk behaviour,...
Background Genetic variants of inosine triphosphatase (ITPA) that confer reduced ITPase activity are associated with protection against ribavirin(RBV)-induced hemolytic anemia in peginterferon(IFN)/RBV-based treatment hepatitis C virus (HCV). Patients showed improved efficacy when treated IFN/RBV. In addition, a genetic polymorphism near the IL28B gene is an response to IFN/RBV treatment. RBV has been important component IFN-containing regimens, and currently recommended combination several...
Multiple sclerosis (MS) is an immune-mediated neurological disease that causes demyelination. The etiology unknown, but patients with a previous viral infection, such as Epstein–Barr virus, have been shown to be at higher risk of developing MS. In contrast, people living HIV lower Hepatitis C virus (HCV) mainly infects the liver, HCV can experience several extrahepatic manifestations and studies association autoimmune conditions neuropathy myelitis. present study aimed investigate MS in...
The objective of this study was to evaluate sick leave and disability pension in patients with chronic hepatitis C virus (HCV) infection as compared a matched general population cohort. Retrospective register study. Nationwide Sweden. This register-based used the Swedish National Patient Register identify working-age HCV 2012 (n=32 021) who were diagnosed between 1999 2007 (n=19 362). Sick data retrieved from Statistics Sweden (1994-2012), up five individuals population. primary outcome...